key: cord-1055972-dglykgkh
authors: Rieder, Marina; Wirth, Luisa; Pollmeier, Luisa; Jeserich, Maren; Goller, Isabella; Baldus, Niklas; Schmid, Bonaventura; Busch, Hans-Joerg; Hofmann, Maike; Thimme, Robert; Rieg, Siegbert; Kern, Winfried; Bode, Christoph; Duerschmied, Daniel; Lother, Achim
title: Serum protein profiling reveals a specific upregulation of the immunomodulatory protein progranulin in COVID-19
date: 2020-11-29
journal: J Infect Dis
DOI: 10.1093/infdis/jiaa741
sha: e2cba16dde2d2806205a9b43c923b93a8518589e
doc_id: 1055972
cord_uid: dglykgkh

BACKGROUND: Severe courses of COVID-19 are associated with elevated levels of interleukin 6. However, there is a growing body of evidence pointing to a broad and more complex disorder of pro-inflammatory and anti-viral responses with disturbed interferon signaling in COVID-19. METHODS: In this prospective single-center registry, we included SARS-CoV-2 positive patients and patients with similar symptoms and severity of disease but negative for SARS-CoV-2 admitted to the emergency department and compared their serum protein expression profiles. RESULTS: Interleukin-6 abundance was similar in SARS-CoV-2 positive patients (n = 24) compared to SARS-CoV-2 negative control (n = 61). In contrast, we observed a specific upregulation of the immunomodulatory protein progranulin (GRN). High GRN abundance was associated with adverse outcomes and increased expression of interleukin-6 in COVID-19. CONCLUSION: The data from this registry reveals that GRN is specifically upregulated in SARS-CoV-2 positive patients while interleukin-6 may serve as marker for disease severity. The potential of GRN as a biomarker and a possible impact of increased GRN expression on interferon signaling, virus elimination, and virus-induced lung tissue damage in COVID-19 should be further explored.

Coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with substantial pulmonary disease up to acute respiratory failure. However, there is a broad range of extrapulmonary manifestations, including thromboembolism, bleeding, myocardial injury, renal failure, gastrointestinal symptoms, neurological disorders, and others [1] . The spectrum of clinical presentations ranges from asymptomatic or mild courses to severe and life-threatening illness requiring intensive care treatment [2] .

Early during the ongoing pandemic, severe courses of COVID-19 have been linked to what is often referred to as cytokine storm and elevated levels of interleukin 6 (IL-6) have been associated with adverse outcomes [3] [4] [5] [6] . Subsequently, inhibition of the IL-6 signaling pathway has been proposed for treatment of COVID-19 and clinical trials evaluating the use of antibodies against IL-6 or IL-6 receptor are ongoing [7] . However, increased levels of IL-6 have been described in numerous conditions including trauma, surgery, sepsis, respiratory failure, myocardial infarction, or post-resuscitation syndrome [8] and can be considered as a general indicator of disease severity. Unraveling distinct changes in serum protein abundance may facilitate our understanding of COVID-19. However, many studies investigating the pathophysiology of SARS-CoV-2 focused on critically ill patients with COVID-19 compared to patients with COVID-19 and moderate symptoms or to healthy individuals. Thus, the goal of the present study was to identify distinct protein expression in serum of patients with COVID-19 versus patients presenting with comparable symptoms and disease severity but tested negative for SARS-CoV-2.

A c c e p t e d M a n u s c r i p t

We performed an investigator-initiated, prospective single-center registry study to evaluate changes in serum protein expression associated with COVID-19 (DRKS00021206, Deutsches Register klinische Studien (DRKS)) conducted at the University Medical Center -University of Freiburg. The protocol of this study conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institutional ethical committee of the University of Freiburg (EK 153/20).

All-comers admitted to the department of emergency medicine of the University Medical Center -University of Freiburg undergoing a throat swab for PCR testing of suspected SARS-CoV-2 infection at the physicians discretion were eligible for inclusion. Written informed consent was obtained from all participants prior to inclusion and before the test results were available. Patients with a negative PCR-test for SARS-CoV-2 served as control group. We analyzed 24 SARS-CoV-2 positive and 61 negative patients that were recruited between the 2nd of April 2020 and the 8th of May 2020.

Characteristics such as medical history, clinical symptoms or previous medication were obtained from all patients enrolled in the study. The severity of illness was assessed using the Sequential Organ Failure Assessment (SOFA) score [9] . Serum samples were obtained at the time point of hospital admission. In addition to the determination of clinical routine parameters, serum samples were analyzed with proximity extension assay (PEA) technology for protein detection and quantification. We performed a standardized 30-days follow-up period after study inclusion. All clinical data gathered during this period was obtained from the electronic patient file. During follow-up, no interventions were conducted for the purpose of this study and all therapeutic and diagnostic procedures were applied as part of standard A c c e p t e d M a n u s c r i p t care at the discretion of the treating physicians. Finally, participants were contacted by phone and asked about the course of disease. Patients who required ICU treatment or died were categorized as severe, inpatients not requiring ICU were categorized as moderate, and outpatients were categorized as mild course of disease.

Protein abundance in serum was determined by proximity extension assay [10] according to the manufacturer's instructions. Briefly, the protein of interest is targeted by oligonucleotide-labeled antibody probes. By binding to the target protein, a pair of probes is brought into close proximity allowing the oligonucleotides to hybridize. The resulting DNA template is detected and quantified by real-time PCR. Relative abundance of each target protein is presented in arbitrary units (Normalized Protein eXpression, NPX), allowing comparison between samples. Proximity extension assay was performed at the ARCADIA core facility at UMC Utrecht (NL) as an Olink certified service provider and technicians were blind for SARS-CoV-2 status of the samples.

For analysis, data were blinded to patient identity. Statistical analyses were performed using SPSS (version 25, IBM, SPSS Statistics, Armonk, USA) and GraphPad Prism 8 (GraphPad Software, San Diego, USA). Continuous variables were tested for normal distribution by using the Shapiro-Wilk test. Data are presented as mean ± standard deviation if found to follow a Gaussian distribution or otherwise as median with interquartile range. Variables following Gaussian distribution were compared using student's t-test, non-normally distributed continuous values by using Mann-Whitney-U test. NPX data was analyzed by student's t-test with Benjamini and Hochberg correction of false discovery rate. Categorical A c c e p t e d M a n u s c r i p t variables were assessed by chi-square test or Fisher's exact test as appropriate. Correlation analysis was performed using the Spearman test for non-parametric data.

Of the 85 patients analyzed, 24 were SARS-CoV-2 positive and 61 SARS-CoV-2 negative.

Main diagnoses for hospital admission of SARS-CoV-2 negative patients included non-COVID-19 infectious diseases, cancer, cardiac disease, and others ( Fig. 1A ). Median age, body mass index, and sex ratio were similar in both groups (Table 1) . We observed a statistically non-significant trend towards a higher occurrence of cough or fever in SARS-CoV-2 positive patients. In addition, blood pressure, respiratory rate, temperature and disease severity as assessed by SOFA score were comparable in SARS-CoV-2 positive and negative patients ( Table 1) . Evaluation of medical history, potential risk factors, and preexisting medication revealed no difference except for a higher rate of premedication with oral anticoagulants or antiplatelet agents in the SARS-CoV-2 negative group (Table 1) .

Outcome categories and detailed outcome parameters (rate of hospital admission, rate of ICU-admission, need of ventilation, mortality) were comparable between both groups (Fig.

1B, Table 1 ). Of all routine laboratory parameters obtained at the time of admission to the emergency department, hemoglobin, hematocrit, AST and ALT were significantly higher in the SARS-CoV-2 positive group compared to SARS-CoV-2 negative patients. In contrast, Troponin T and proBNP levels were significantly higher in the control group (Table 2) , likely reflecting the rate of acute coronary syndromes and heart failure as reasons for hospital admission in SARS-CoV-2 negative patients ( Fig 1A) . Importantly, we did not find differences in IL-6 expression between SARS-CoV-2 positive and negative patients (Fig.1C) .

A c c e p t e d M a n u s c r i p t

To identify potentially COVID-19-related proteins, we performed a proximity extension assay-based screening of 92 candidate proteins from serum samples taken at hospital admission ( Figure 2A-B, Supplemental Figure 1 ). Sample-to-sample correlation was significantly higher in the SARS-CoV-2 positive group compared to the control group (Supplemental Figure 1A- 

Interestingly, GRN was excessively increased (3.3-fold above mean of SARS-CoV-2 positive patients) in the one COVID-19 patient that died during the 30-days follow-up period (Fig.   2C ). To follow this finding, we assessed outcomes of SARS-CoV-2 positive patients with high (above 50 th percentile) or low (below 50 th percentile) GRN expression. The rate of severe courses was significantly higher in patients with high GRN expression (Fig. 3A) .

Patients with high GRN expression showed higher maximum serum creatinine and IL-6 levels as surrogate parameters for disease severity (Fig. 3B-C) . Interestingly, levels of GRN and maximum IL-6 in SARS-CoV-2 positive patients were strongly correlated with each other ( Figure 3D ). To identify potential pathophysiological processes associated with increased A c c e p t e d M a n u s c r i p t GRN expression, we searched for other co-expressed factors in serum of SARS-CoV-2 positive patients (Fig. 4) . Among the proteins showing the most significant positive correlation with GRN were growth/differentiation factor 15 (GDF-15), urokinase-type plasminogen activator (uPA) and urokinase-type plasminogen activator receptor (U-PAR).

Furthermore tumor necrosis factor receptors 1 and 2 (TNF-R1, TNF-R2), that serve as GRN receptors as well, were strongly correlated with GRN abundance (Fig. 4) .

We observed a higher number of monocytes in blood from SARS-CoV-2 positive patients with high GRN expression ( Fig 5A) and GRN expression was significantly correlated with monocyte count (Fig. 5B) . To confirm the cellular source of GRN in SARS-CoV-2 positive patients we assessed a very recently published dataset [11] on single cell mRNA expression in peripheral blood mononuclear cells from COVID-19 patients and healthy donors (Fig. 5C ).

In monocytes from patients with a moderate or severe course of COVID-19, GRN expression was 2.0-or 1.9-fold increased, respectively, when compared to healthy individuals (Fig. 5C ).

In contrast, no or only minor changes in GRN expression were detectable in natural killer cells, T cells, or B cells from patients with COVID-19 (Fig. 5C ).

In this study, we compared serum protein expression in patients with COVID-19 to patients with comparable symptoms and disease severity but negative for SARS-CoV-2. We identified the immunomodulatory factor progranulin (GRN) and TNFRSF10C to be specifically regulated in patients with A c c e p t e d M a n u s c r i p t

We observed a specific upregulation of GRN in SARS-CoV-2 positive patients compared to patients with comparable symptoms and disease severity but negative for SARS-CoV-2.

This supports an earlier report describing an upregulation of GRN in patients with severe COVID-19 but not in patients with other diseases when compared to healthy controls [12] . In contrast, we found no difference in IL-6 abundance in SARS-CoV-2 positive versus negative patients. This important finding is in line with a recent report describing that the plasma cytokine profile of severe COVID-19 was similar to ARDS or sepsis [13] . Thus, while IL-6 might serve as a marker for disease severity in COVID-19, it is in contrast to GRN not specifically upregulated in patients with moderate symptoms. However, though promising, the usability of GRN as a biomarker in COVID-19 requires further investigation, including patients with a broader spectrum of disease severity.

There is a growing body of evidence pointing to a broad and more complex disorder of proinflammatory and anti-viral responses in COVID-19 [7] . Recent studies have shown that interferon signaling seems to take a critical role in COVID-19. Interferons are crucial for the immune response to viral infections as they induce the synthesis of proteins interfering with viral replication [14] . Upon viral infection, most cell types are able to secret interferons type I (IFN-α and IFN-β), whereas interferon type II (INF-γ) is only produced by NK cells and activated T cells [14, 15] . Studies on SARS coronavirus (SARS-CoV), causing the 2003 pandemic, demonstrated antiviral effects of IFN-β at high concentrations [16, 17] . Likewise, treatment with type I and III interferons reduced virus replication in cell cultures infected with SARS-CoV-2 [18, 19] . However, current research shows that induction of interferons in cells infected with SARS-CoV-2 is impaired [18, 20, 21] . Transcriptional profiling of human airway epithelial cells revealed an upregulation of IL-6 and other pro-inflammatory cytokines but a repression of interferon I and III signaling after SARS-CoV-2 infection [18] . In patients with COVID-19, interferon production by mononuclear cells was reduced [22, 23] . Suppression of the translational machinery by SARS-CoV-2 [24] and auto-antibodies against type I interferons [25] have been proposed as potential mechanisms involved. The lack of A c c e p t e d M a n u s c r i p t interferons is associated with a persistent blood viral load and an increase of TNF-α and IL-6 [26] , suggesting that the diminished interferon response contributes to impaired virus elimination and disease progression in COVID-19. Early clinical data indicate a potential benefit of subcutaneously administered interferon beta on the course of COVID-19 and further studies are currently ongoing [27] . However, the optimal IFN-I subtype, dose, timing, and route of administration appear to be crucial and remain to be investigated [27] .

GRN is the common precursor of the granulin peptide family [28] . It is a pleiotrophic growth factor and immune-regulatory molecule expressed in a broad range of tissues and cell types such as epithelia, bone marrow and various immune cells including T-cells, DCs, monocytes and macrophages [28] . In SARS-CoV-2 positive patients, GRN abundance was associated with higher blood monocyte counts. Single cell data shows an upregulation of GRN mRNA expression in blood monocytes [11] and in pulmonary macrophages after SARS-CoV-2 infection [29] , suggesting that myeloid cells are the primary source of GRN in COVID-19. By binding to the membrane bound receptors TNF-R1, TNF-R2 or TLR9, GRN exhibits a variety of functions in the innate and adaptive immune system [28] . In the adaptive immune system, GRN is crucial for T-cell regulation since it promotes the differentiation of CD4+ T cells into Foxp3+ Tregs and protects Tregs from negative regulation by TNF-alpha [30] . GRN prevents regulatory NK cell cytotoxicity against antiviral T cells [31] and inhibits LPS-mediated IL-6 and TNF-α secretion from macrophages [32, 33] .

GRN has contrasting roles in bacterial or viral infections that may contribute to the pathophysiology of COVID-19: GRN contributes to host defense against bacterial pneumonia and sepsis by promoting macrophage recruitment and bacterial clearance [34, 35] . On the other hand, it was shown that GRN mRNA is induced in the lungs of mice after influenza infection [36] and that GRN is upregulated in clinical and experimental influenza in a disease-severity dependent manner [37] , similar to what we observed here in COVID-19.

A c c e p t e d M a n u s c r i p t and mortality due to an enhanced influx of neutrophils and monocytes/macrophages and a consequently significant increase of pulmonary IL-6 and other cytokines [37] . In line with this, we observed a positive correlation of GRN with IL-6 abundance and disease severity in patients with COVID-19. Importantly, deterioration of viral infections by GRN are accompanied by an impaired type I interferon production due to inhibition of NF-κB and IRF3 signaling [38] , similar to what has been described in SARS-CoV-2 infection [26] . GRN neutralizing antibodies protect against influenza virus-induced lethality in mice [38] . Thus, we conclude that restoring interferon signaling by inhibition of GRN may have beneficial effects on COVID-19 that should be further explored.

Among others, GRN exerts its downstream effects by activation of TNF-R1 and TNF-R2 [28] .

Interestingly, upregulation of GRN was associated with increased abundance of TNF-R1 and TNF-R2 in SARS-CoV-2 positive patients, implying a possible feed forward mechanism.

Moreover, we found that another member of the TNF-receptor superfamily, TNFRSF10C, A c c e p t e d M a n u s c r i p t

In conclusion, the data from this prospective registry reveals that GRN is specifically upregulated in SARS-CoV-2 positive patients compared to patients presenting with comparable symptoms and disease severity but tested negative for SARS-CoV-2. The potential of GRN as a biomarker and a possible impact of increased GRN expression on interferon signaling, virus elimination, and virus-induced lung tissue damage in COVID-19

should be further explored. and patients with other main diagnosis but negative for SARS-CoV-2 (n = 61) admitted to the emergency department were included in a prospective registry (A). Patient outcomes were categorized as mild, moderate or severe (B). Serum levels of interleukin-6 was determined in routine testing (C). .05 by student's t-test) and Pearson correlation of blood monocyte count with GRN expression (B) were determined. Cell typespecific changes in GRN mRNA expression were derived from a previously published single cell RNA-seq [11] from peripheral blood mononuclear cells from patients with moderate (n=7) or severe (n=4) COVID-19 and healthy donors (n=5) (C).

Extrapulmonary manifestations of COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

The Definition and Risks of Cytokine Release Syndrome in 11 COVID-19-Affected Critically Ill Patients with Pneumonia: Analysis of Disease Characteristics

Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China

Immunology of COVID-19: Current State of the Science

Interleukin-6 in surgery, trauma, and critical care part II: clinical implications

Serial evaluation of the SOFA score to predict outcome in critically ill patients

Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability

Single-cell landscape of immunological responses in patients with COVID-19

Proteomic and Metabolomic Characterization of COVID-19

Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis

Type I interferons in infectious disease

Regulation of antiviral T cell responses by type I interferons

Treatment of SARS with human interferons

Interferon-beta 1a and SARS coronavirus replication

Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures

Interferon-beta-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Attenuated Interferon and Proinflammatory Response in SARS-CoV-2-Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1

Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans

SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19

Insights into the role of progranulin in immunity, infection, and inflammation

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice

Progranulin prevents regulatory NK cell cytotoxicity against antiviral T cells

Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice

Prevention of LPS-induced acute lung injury in mice by progranulin

Progranulin Plays a Central Role in Host Defense during Sepsis by Promoting Macrophage Recruitment

Contribution of Progranulin to Protective Lung Immunity During Bacterial Pneumonia

A systems analysis identifies a feedforward inflammatory circuit leading to lethal influenza infection

Progranulin aggravates pulmonary immunopathology during influenza virus infection

Induction of PGRN by influenza virus inhibits the antiviral immune responses through downregulation of type I interferons signaling

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t